408 related articles for article (PubMed ID: 30281314)
1. Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.
Collier MA; Junkins RD; Gallovic MD; Johnson BM; Johnson MM; Macintyre AN; Sempowski GD; Bachelder EM; Ting JP; Ainslie KM
Mol Pharm; 2018 Nov; 15(11):4933-4946. PubMed ID: 30281314
[TBL] [Abstract][Full Text] [Related]
2. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.
Junkins RD; Gallovic MD; Johnson BM; Collier MA; Watkins-Schulz R; Cheng N; David CN; McGee CE; Sempowski GD; Shterev I; McKinnon K; Bachelder EM; Ainslie KM; Ting JP
J Control Release; 2018 Jan; 270():1-13. PubMed ID: 29170142
[TBL] [Abstract][Full Text] [Related]
3. Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.
Chen N; Gallovic MD; Tiet P; Ting JP; Ainslie KM; Bachelder EM
J Control Release; 2018 Nov; 289():114-124. PubMed ID: 30261204
[TBL] [Abstract][Full Text] [Related]
4. Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.
Chen N; Johnson MM; Collier MA; Gallovic MD; Bachelder EM; Ainslie KM
J Control Release; 2018 Mar; 273():147-159. PubMed ID: 29407676
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of acetalated-dextran microparticle fabrication methods for a clinically translatable subunit-based influenza vaccine.
Pena ES; Batty CJ; Hendy DA; Yang S; Ontiveros-Padilla L; Stiepel RT; Ting JP; Ainslie KM; Bachelder EM
Int J Pharm; 2024 Mar; 652():123836. PubMed ID: 38266940
[TBL] [Abstract][Full Text] [Related]
6. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8
Watkins-Schulz R; Tiet P; Gallovic MD; Junkins RD; Batty C; Bachelder EM; Ainslie KM; Ting JPY
Biomaterials; 2019 Jun; 205():94-105. PubMed ID: 30909112
[TBL] [Abstract][Full Text] [Related]
7. Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicit protective immune responses against influenza viruses.
Zhang X; Shi H; Hendy DA; Bachelder EM; Ainslie KM; Ross TM
bioRxiv; 2024 Feb; ():. PubMed ID: 38464191
[TBL] [Abstract][Full Text] [Related]
8. In Vivo and Cellular Trafficking of Acetalated Dextran Microparticles for Delivery of a Host-Directed Therapy for Salmonella enterica Serovar Typhi Infection.
Johnson MM; Collier MA; Hoang KV; Pino EN; Graham-Gurysh EG; Gallovic MD; Zahid MSH; Chen N; Schlesinger L; Gunn JS; Bachelder EM; Ainslie KM
Mol Pharm; 2018 Nov; 15(11):5336-5348. PubMed ID: 30296381
[TBL] [Abstract][Full Text] [Related]
9. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.
Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Dolzhikova IV; Stanhope-Baker P; Naroditsky BS; Gudkov AV; Logunov DY; Gintsburg AL
PLoS One; 2016; 11(5):e0155650. PubMed ID: 27187797
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis.
Schully KL; Bell MG; Prouty AM; Gallovic MD; Gautam S; Peine KJ; Sharma S; Bachelder EM; Pesce JT; Elberson MA; Ainslie KM; Keane-Myers A
Int J Pharm; 2015 Nov; 495(2):849-61. PubMed ID: 26428631
[TBL] [Abstract][Full Text] [Related]
11. TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
McKay PF; King DF; Mann JF; Barinaga G; Carter D; Shattock RJ
PLoS One; 2016; 11(2):e0148984. PubMed ID: 26862758
[TBL] [Abstract][Full Text] [Related]
12. Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications.
Moore KM; Batty CJ; Stiepel RT; Genito CJ; Bachelder EM; Ainslie KM
ACS Appl Mater Interfaces; 2020 Sep; 12(35):38950-38961. PubMed ID: 32805875
[TBL] [Abstract][Full Text] [Related]
13. The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells.
Gutjahr A; Papagno L; Nicoli F; Kanuma T; Kuse N; Cabral-Piccin MP; Rochereau N; Gostick E; Lioux T; Perouzel E; Price DA; Takiguchi M; Verrier B; Yamamoto T; Paul S; Appay V
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944257
[TBL] [Abstract][Full Text] [Related]
14. Multiplexed electrospray enables high throughput production of cGAMP microparticles to serve as an adjuvant for a broadly acting influenza vaccine.
Batty CJ; Gallovic MD; Williams J; Ross TM; Bachelder EM; Ainslie KM
Int J Pharm; 2022 Jun; 622():121839. PubMed ID: 35623484
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
[TBL] [Abstract][Full Text] [Related]
16. Delivery of STING agonists for adjuvanting subunit vaccines.
Van Herck S; Feng B; Tang L
Adv Drug Deliv Rev; 2021 Dec; 179():114020. PubMed ID: 34756942
[TBL] [Abstract][Full Text] [Related]
17. Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight.
Chen N; Collier MA; Gallovic MD; Collins GC; Sanchez CC; Fernandes EQ; Bachelder EM; Ainslie KM
Int J Pharm; 2016 Oct; 512(1):147-157. PubMed ID: 27543351
[TBL] [Abstract][Full Text] [Related]
18. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways.
Johnson BM; Uchimura T; Gallovic MD; Thamilarasan M; Chou WC; Gibson SA; Deng M; Tam JW; Batty CJ; Williams J; Matsushima GK; Bachelder EM; Ainslie KM; Markovic-Plese S; Ting JP
J Immunol; 2021 May; 206(9):2015-2028. PubMed ID: 33820855
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
